{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:21:38Z","timestamp":1791598898117,"version":"4.3.4"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"43","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the French National Research Agency Fighting Heart Failure","award":["ANR-15-RHU-0004"],"award-info":[{"award-number":["ANR-15-RHU-0004"]}]},{"name":"the French PIA project Lorraine Universit\u00e9 d\u2019Excellence GEENAGE","award":["ANR-15-IDEX-04-LUE"],"award-info":[{"award-number":["ANR-15-IDEX-04-LUE"]}]},{"name":"the Contrat de Plan Etat R\u00e9gion Lorraine and FEDER IT2MP"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Worsening kidney function is a key prognostic factor in heart failure (HF) with reduced ejection fraction (HFrEF). However, associations between kidney function trajectories and HF-related events remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Longitudinal changes in estimated glomerular filtration rate (eGFR) before and after a HF-related event, defined as HF hospitalization or HF death, were examined using individual patient data from two clinical trials (EPHESUS and EMPHASIS-HF) and a real-world cohort (BARCELONA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HF-related events occurred in 14.1% of 8587 patients [EPHESUS\/EMPHASIS-HF; median follow-up 17.1 (12.4\u201322.7) months] and 33.8% of 2048 patients [BARCELONA; median 47.0 (18.8\u201390.6) months]. In EPHESUS and EMPHASIS-HF, patients who experienced an HF-related event had a steeper decline in eGFR in the year preceding the event (average \u22124.83\u2005mL\/min\/1.73\u2005m\u00b2\/year) compared with those who did not have an HF-related event (\u22121.18\u2005mL\/min\/1.73\u2005m\u00b2\/year). Over the 1 year following an HF-related event, eGFR continued to decline, though at a slower rate (average \u22123.45\u2005mL\/min\/1.73\u2005m\u00b2\/year). Similar kidney function trajectories were observed in BARCELONA (average eGFR decline \u22121.35\u2005mL\/min\/1.73\u2005m\u00b2\/year in patients without HF event vs \u22125.77\u2005mL\/min\/1.73\u2005m\u00b2\/year 1 year before an event and \u22123.04\u2005mL\/min\/1.73\u2005m\u00b2\/year over the year after an event). Worsening New York Heart Association class paralleled steeper eGFR decline prior to HF events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In HFrEF, kidney function decline may precede a HF hospitalization or death by up to 1 year, linking to symptomatic congestion. Monitoring eGFR slopes rather than relying solely on specific cut-off values may allow early detection of at-risk patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaf457","type":"journal-article","created":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T12:14:42Z","timestamp":1753013682000},"page":"4583-4593","source":"Crossref","is-referenced-by-count":21,"title":["Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction"],"prefix":"10.1093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0008-2256","authenticated-orcid":false,"given":"Masatake","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Lorraine, and the CardioRenal Integration Clinical Investigation Center, INSERM, CHU de Nancy , Rue du Morvan, 54500 Vandoeuvre-les-Nancy ,","place":["France"]},{"name":"Department of Cardiology, Tokyo Medical University , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3044-197X","authenticated-orcid":false,"given":"Antoni","family":"Bayes-Genis","sequence":"additional","affiliation":[{"name":"Heart Institute, University Hospital Germans Trias i Pujol, Departament de Medicina, Universitat Aut\u00f2noma de Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Duarte","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, and the CardioRenal Integration Clinical Investigation Center, INSERM, CHU de Nancy , Rue du Morvan, 54500 Vandoeuvre-les-Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J V","family":"McMurray","sequence":"additional","affiliation":[{"name":"BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, and the CardioRenal Integration Clinical Investigation Center, INSERM, CHU de Nancy , Rue du Morvan, 54500 Vandoeuvre-les-Nancy ,","place":["France"]},{"name":"Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto , Porto ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2212-4007","authenticated-orcid":false,"given":"Stuart J","family":"Pocock","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, London School of Hygiene and Tropical Medicine , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J","family":"Van Veldhuisen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5601-9611","authenticated-orcid":false,"given":"Josep","family":"Lup\u00f3n","sequence":"additional","affiliation":[{"name":"Heart Institute, University Hospital Germans Trias i Pujol, Departament de Medicina, Universitat Aut\u00f2noma de Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-275X","authenticated-orcid":false,"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Michigan School of Medicine , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, and the CardioRenal Integration Clinical Investigation Center, INSERM, CHU de Nancy , Rue du Morvan, 54500 Vandoeuvre-les-Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3278-2057","authenticated-orcid":false,"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, and the CardioRenal Integration Clinical Investigation Center, INSERM, CHU de Nancy , Rue du Morvan, 54500 Vandoeuvre-les-Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"2025111318572732000_ehaf457-B1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jacc.2022.11.023","article-title":"Worsening heart failure: nomenclature, epidemiology, and future directions","volume":"81","author":"Greene","year":"2023","journal-title":"JACC Review Topic of the Week. J Am Coll Cardiol"},{"key":"2025111318572732000_ehaf457-B2","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1001\/jama.2021.20739","article-title":"Contextualizing risk among patients with heart failure","volume":"326","author":"Greene","year":"2021","journal-title":"JAMA"},{"key":"2025111318572732000_ehaf457-B3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrcardio.2015.14","article-title":"The vulnerable phase after hospitalization for heart failure","volume":"12","author":"Greene","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"2025111318572732000_ehaf457-B4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/ejhf.2408","article-title":"A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction\u2014insights from the ESC-HFA EORP Heart Failure Long-Term Registry","volume":"24","author":"Kap\u0142on-Cie\u015blicka","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2025111318572732000_ehaf457-B5","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/ejhf.1697","article-title":"Evaluation of kidney function throughout the heart failure trajectory\u2014a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Mullens","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2025111318572732000_ehaf457-B6","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/eurheartj\/ehv010","article-title":"The kidney in heart failure: an update","volume":"36","author":"Damman","year":"2015","journal-title":"Eur Heart J"},{"key":"2025111318572732000_ehaf457-B7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"2025111318572732000_ehaf457-B8","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/ejhf.872","article-title":"Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"19","author":"Harjola","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2025111318572732000_ehaf457-B9","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1002\/ejhf.2638","article-title":"Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trial","volume":"24","author":"Chatur","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2025111318572732000_ehaf457-B10","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2025111318572732000_ehaf457-B11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2025111318572732000_ehaf457-B12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.jacc.2018.05.042","article-title":"Dynamic trajectories of left ventricular ejection fraction in heart failure","volume":"72","author":"Lup\u00f3n","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2025111318572732000_ehaf457-B13","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jchf.2024.01.004","article-title":"Trajectories of kidney function in heart failure over a 15-year follow-up: clinical profiling and mortality","volume":"12","author":"Zamora","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2025111318572732000_ehaf457-B14","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2025111318572732000_ehaf457-B15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1053\/j.ajkd.2025.01.011","article-title":"Association of estimated GFR slope and heart failure progression in older adults","volume":"85","author":"Kohansal","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"2025111318572732000_ehaf457-B16","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1002\/ejhf.1968","article-title":"Acceleration of kidney function decline after incident hospitalization with cardiovascular disease: the Stockholm CREAtinine measurements (SCREAM) project","volume":"22","author":"Ishigami","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2025111318572732000_ehaf457-B17","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1001\/jama.2014.6634","article-title":"Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality","volume":"311","author":"Coresh","year":"2014","journal-title":"JAMA"},{"key":"2025111318572732000_ehaf457-B18","doi-asserted-by":"publisher","first-page":"e003825","DOI":"10.1161\/CIRCHEARTFAILURE.116.003825","article-title":"Heart failure increases the risk of adverse renal outcomes in patients with normal kidney function","volume":"10","author":"George","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2025111318572732000_ehaf457-B19","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1161\/CIRCULATIONAHA.117.028814","article-title":"Cardiorenal syndrome revisited","volume":"138","author":"Zannad","year":"2018","journal-title":"Circulation"},{"key":"2025111318572732000_ehaf457-B20","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1161\/CIRCULATIONAHA.108.783910","article-title":"Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures","volume":"118","author":"Zile","year":"2008","journal-title":"Circulation"},{"key":"2025111318572732000_ehaf457-B21","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/ejhf.2103","article-title":"Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta-regression in the past four decades","volume":"23","author":"Kimmoun","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2025111318572732000_ehaf457-B22","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jacc.2008.08.080","article-title":"Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease","volume":"53","author":"Damman","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2025111318572732000_ehaf457-B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/ajplegacy.1949.157.1.1","article-title":"Effect of increased renal venous pressure on renal function","volume":"157","year":"1949","journal-title":"Am J Physiol"},{"key":"2025111318572732000_ehaf457-B24","doi-asserted-by":"publisher","first-page":"F279","DOI":"10.1152\/ajprenal.1980.238.4.F279","article-title":"Renal interstitial pressure and sodium excretion during renal vein constriction","volume":"238","author":"Burnett","year":"1980","journal-title":"Am J Physiol"},{"key":"2025111318572732000_ehaf457-B25","doi-asserted-by":"publisher","first-page":"17757","DOI":"10.1038\/s41598-018-36189-3","article-title":"Selective abdominal venous congestion induces adverse renal and hepatic morphological and functional alterations despite a preserved cardiac function","volume":"8","author":"Cops","year":"2018","journal-title":"Sci Rep"},{"key":"2025111318572732000_ehaf457-B26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jacc.2008.05.068","article-title":"Importance of venous congestion for worsening of renal function in advanced decompensated heart failure","volume":"53","author":"Mullens","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2025111318572732000_ehaf457-B27","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jchf.2017.05.006","article-title":"Intrarenal flow alterations during transition from euvolemia to intravascular volume expansion in heart failure patients","volume":"5","author":"Nijst","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2025111318572732000_ehaf457-B28","doi-asserted-by":"publisher","first-page":"F958","DOI":"10.1152\/ajprenal.00476.2015","article-title":"Everything we always wanted to know about furosemide but were afraid to ask","volume":"310","author":"Huang","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025111318572732000_ehaf457-B29","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/0009-9236(95)90222-8","article-title":"Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure","volume":"57","author":"Vargo","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"2025111318572732000_ehaf457-B30","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1002\/ehf2.13929","article-title":"Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction","volume":"9","author":"Girerd","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2025111318572732000_ehaf457-B31","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.acvd.2020.03.018","article-title":"Practical management of worsening renal function in outpatients with heart failure and reduced ejection fraction: statement from a panel of multidisciplinary experts and the Heart Failure Working Group of the French Society of Cardiology","volume":"113","author":"Mewton","year":"2020","journal-title":"Arch Cardiovasc Dis"},{"key":"2025111318572732000_ehaf457-B32","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ndt\/gfae004","article-title":"When to use either spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases","volume":"39","author":"Kobayashi","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2025111318572732000_ehaf457-B33","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1093\/eurheartj\/ehaf225","article-title":"Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease","volume":"46","author":"Kobayashi","year":"2025","journal-title":"Eur Heart J"},{"key":"2025111318572732000_ehaf457-B34","doi-asserted-by":"publisher","first-page":"132477","DOI":"10.1016\/j.ijcard.2024.132477","article-title":"Adverse events associated with early initiation of eplerenone in patients hospitalized for acute heart failure","volume":"415","author":"Kobayashi","year":"2024","journal-title":"Int J Cardiol"},{"key":"2025111318572732000_ehaf457-B35","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2025111318572732000_ehaf457-B36","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2025111318572732000_ehaf457-B37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jacc.2024.10.091","article-title":"Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF trial","volume":"85","author":"Mc Causland","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025111318572732000_ehaf457-B38","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2025111318572732000_ehaf457-B39","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/43\/4583\/63894462\/ehaf457.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/43\/4583\/63894462\/ehaf457.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T23:57:33Z","timestamp":1763078253000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/46\/43\/4583\/8219396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":39,"journal-issue":{"issue":"43","published-online":{"date-parts":[[2025,7,30]]},"published-print":{"date-parts":[[2025,11,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf457","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,14]]},"published":{"date-parts":[[2025,7,30]]}}}